Compared with the first 3 years of denosumab treatment, a longer duration of denosumab therapy was associated with further decrease in nonvertebral fracture rate, which was sustained through 10 years of treatment.
Gender-affirming hormone treatment may lead to changes in bone turnover markers in transgender men and women, but overall does not have negative effects on bone health.
Osteopenia was found in more than 25% of both men and women, suggesting that more osteoporosis screening and prevention programs are needed in middle-age individuals.
An osteoporosis diagnosis may affect a patient’s mental health because of diminished quality of life, fear of falling, embarrassment about posture changes, or general depression about the diagnosis.
Even without a history of fragility fracture, the presence of osteoporosis is associated with substantially lower health-related quality of life.
Parity and lactation had a neutral effect on the risk for fragility fractures or radiographic vertebral compression fractures over 10 years of follow-up.
Researchers used epidemiologic evidence to better understand the risk for osteoporosis and osteoarthritis in patients with cerebral palsy.
The FRAX fracture risk tool can stratify fracture risk equally well among women receiving aromatase inhibitor (AI) therapy for breast cancer and nonusers of AI therapy.
Roux-en-Y gastric bypass is associated with a higher risk for nonvertebral fractures compared with adjustable gastric banding.
Patients with or at high risk for osteoporosis should take the lowest possible dosage of vitamin D3 with the shortest possible interval.
